Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Biocon's interest expense for the
three
months ended in Jun. 2026 was ₹ -2,132 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was ₹-9,268 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Biocon's Operating Income for the
three
months ended in Jun. 2026 was ₹ 2,998 Mil. Biocon's Interest Expense for the
three
months ended in Jun. 2026 was ₹ -2,132 Mil.
Biocon's Interest Coverage for the quarter that ended in Jun. 2026 was 1.41.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Biocon Interest Expense Historical Data
* Premium members only.
The historical data trend for Biocon's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-9,268 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocon (NSE:BIOCON) has a Interest Expense of ₹-9,268 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Biocon and its competitors.
Is Biocon's Interest Expense too high?
Biocon's current Interest Expense is ₹-9,268 Mil. Overall, Biocon has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocon's Interest Expense compare to VRTX and REGN?
Biocon's Interest Expense of ₹-9,268 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Biocon and its competitors. Biocon's current Interest Expense is ₹-9,268 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocon stock overvalued right now?
Based on GuruFocus' analysis, Biocon (NSE:BIOCON) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹333.27, compared to a current price of ₹426.35 — trading 27.9% above its estimated fair value. The current Interest Expense is ₹-9,268 Mil. Biocon's overall GF Score™ is 88/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Biocon (NSE:BIOCON), the current Interest Expense is ₹-9,268 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocon (NSE:BIOCON) Overvalued in 2026?
Based on GuruFocus' analysis, Biocon stock appears to be overvalued.
The current stock price of ₹426.35 is trading 27.9% above its estimated GF Value™ of ₹333.27.
GuruFocus considers Biocon to be Modestly Overvalued.
Key valuation signals for NSE:BIOCON:
Interest Expense: ₹-9,268 Mil
GF Value™: ₹333.27 vs. price of ₹426.35 (27.9% above fair value)
No single metric tells the full story. See the NSE:BIOCON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
88GF Score
Get the complete analysis for NSE:BIOCON
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BIOCON has been successfully added to your 
